{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:52:24Z","timestamp":1782993144610,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To evaluate the use of pyridostigmine in presence of contraindications, and the use of concomitant potentially contraindicated drugs in a cohort of patients affected by Myasthenia Gravis (MG) in the Italian Regions of Lazio, Tuscany, and Umbria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective cohort study. A multivariate logistic regression model was used to evaluate the determinants of pyridostigmine and of potentially contraindicated drugs use in MG patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 591 incident pyridostigmine users affected by MG, 91 (15.4%) had at least one of the contraindications considered at the first prescription of pyridostigmine. Patients prescribed with pyridostigmine in presence of contraindications were more frequently affected by diabetes, obesity, and renal diseases. Age 75+ years (odds ratio, OR 4.94, 95% confidence interval, CI 1.60\u201315.22 for Latium; OR 3.78, 95%CI: 1.26\u201311.34 for Tuscany; OR 5.83, 95%CI 1.19\u201328.52 for Umbria), the presence of at least one specific comorbidity (OR 3.93; 95%CI 1.68\u20139.17 for Latium), and polytherapy (6+ drugs, OR 4.90, 95%CI: 1.35\u201317.85 for Tuscany) were found to be significantly associated with pyridostigmine use in presence of contraindications. Among patients affected by MG, 1,483 (62.6%) were treated with potentially contraindicated drugs in the first year of follow-up (67.06.9% in Latium; 59% in Tuscany; 57.6% in Umbria). Patients aged 75+ years, those with at least one specific complication or comorbidity, and those exposed to polytherapy were more likely to be treated with a potential contraindicated drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Among incident users of pyridostigmine, more than 15% of patients have at least one of the contraindications considered, and among patients diagnosed with MG, in the first year of follow-up &amp;gt;60% of subjects were treated with potentially contraindicated drugs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1293626","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:11:40Z","timestamp":1703131900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Potentially inappropriate drug use in myasthenia gravis: a real-world population-based cohort study in Italy"],"prefix":"10.3389","volume":"14","author":[{"given":"Giada","family":"Crescioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Finocchietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Brunori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sciancalepore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Addis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Vannacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Kirchmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The CAESAR study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s1043-0679(99)70018-3","article-title":"Myasthenia gravis: clinical features, pathogenesis, evaluation, and medical management","volume":"11","author":"Heitmiller","year":"1999","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"ref4","volume-title":"Myasthenia Gravis","author":"Beloor Suresh","year":"2023"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"ref7","year":"2016"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/mus.27346","article-title":"Antibiotics in myasthenia gravis: thinking outside the black box","volume":"64","author":"Cea","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.nmd.2022.09.002","article-title":"The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study","volume":"32","author":"Remijn-Nelissen","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1590\/0004-282X20190189","article-title":"Celebrating the 70 years of pyridostigmine on therapy of myasthenia gravis: historical aspects of the preliminary trials","volume":"78","author":"Lorenzoni","year":"2020","journal-title":"Arq Neuropsiquiatr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fdsfr.2022.1041275","article-title":"Riluzole use in presence of contraindications in adults affected by amyotrophic lateral sclerosis and its off-label use in other motor neuron diseases: findings from an Italian multicentre study (the CAESAR project)","volume":"2","author":"Crescioli","year":"2022","journal-title":"Front Drug Saf Regul"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13181-018-0669-1","article-title":"Cholinergic crisis caused by cholinesterase inhibitors: a retrospective nationwide database study","volume":"14","author":"Ohbe","year":"2018","journal-title":"J Med Toxicol Off J Am Coll Med Toxicol"},{"key":"ref15","year":"2020"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","article-title":"Myasthenia gravis and the neuromuscular junction","volume":"26","author":"Querol","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fnmol.2020.00156","article-title":"Pathomechanisms and clinical implications of Myasthenic syndromes exacerbated and induced by medical treatments","volume":"13","author":"Krenn","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ncpneuro0988","article-title":"Is it safe to use statins in patients with myasthenia gravis?","volume":"5","author":"Gilhus","year":"2009","journal-title":"Nat Clin Pract Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1111\/ene.14996","article-title":"The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency","volume":"28","author":"Trillenberg","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.neuropharm.2009.07.031","article-title":"Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness","volume":"57","author":"Harnett","year":"2009","journal-title":"Neuropharmacology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.medcli.2023.01.006","article-title":"Levofloxacin as a possible cause of myasthenic crisis","volume":"160","author":"Dur\u00e1n Barata","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Saf"},{"key":"ref25","year":"2018"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review","volume":"268","author":"Lotan","year":"2021","journal-title":"J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"CD002828","DOI":"10.1002\/14651858.CD002828.pub2","article-title":"Corticosteroids for myasthenia gravis","volume":"2011","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/ajhp\/zxac343","article-title":"Myasthenia gravis: what does a pharmacist need to know?","volume":"80","author":"Marriott","year":"2023","journal-title":"Off J Am Soc Heal Pharm"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2044.2008.05865.x","article-title":"Basic principles of neuromuscular transmission","volume":"64","author":"Martyn","year":"2009","journal-title":"Anaesthesia"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1293626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:11:44Z","timestamp":1703131904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1293626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":30,"alternative-id":["10.3389\/fneur.2023.1293626"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1293626","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"article-number":"1293626"}}